ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.6715
-0.06%
Brent Oil
83.445
0.29%
Bitcoin
66,257.77
1.56%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Mustang Bio Inc (MBIO)

  7. Mustang Bio Inc (MBIO) Noticias

MBIO

Mustang Bio (MBIO)

Mustang Bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MBIO
FechaHoraFuenteTítuloSímboloCompañía
13/05/202405:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
02/05/202415:01GlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
29/04/202419:00GlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
28/03/202408:00GlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
11/03/202415:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
11/03/202415:05GlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
11/03/202415:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
07/03/202406:30GlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
11/01/202407:30GlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
19/12/202315:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
11/12/202320:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
11/12/202307:30GlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
14/11/202315:05GlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
03/11/202314:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MBIOMustang Bio Inc
02/11/202308:28GlobeNewswire Inc.Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
30/10/202313:15GlobeNewswire Inc.Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
30/10/202309:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
26/10/202311:30GlobeNewswire Inc.Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
26/10/202308:00GlobeNewswire Inc.Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaNASDAQ:MBIOMustang Bio Inc
14/08/202315:01GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
14/08/202315:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBIOMustang Bio Inc
07/07/202315:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
30/06/202307:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MBIOMustang Bio Inc
15/05/202315:01GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
28/04/202315:19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MBIOMustang Bio Inc
28/04/202315:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MBIOMustang Bio Inc
14/04/202315:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MBIOMustang Bio Inc
06/04/202315:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:MBIOMustang Bio Inc
03/04/202315:50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MBIOMustang Bio Inc
30/03/202315:10GlobeNewswire Inc.Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
 Showing the most relevant articles for your search:NASDAQ:MBIO

Su Consulta Reciente

NYSE
IIM
Invesco Value Municipal ...
LSE
80WS
LSE
62IR
Nestle Fin 21
USOTC
RAYT
Rayont (CE)
USOTC
NYLE
Nyle (CE)
NASDAQ
AAZDPXX
Goldman Sachs Bank Usa P...
NASDAQ
OSCID
HITB
NEARBTC
NEAR Protocol
LSE
DJEU
Lyxor Djia $
EU
ALGEV
Gevelot
COIN
JSMUST
Joseon Mun
LSE
H3XU
KONEX
232830
Secucen
HITB
DUSKUSDT
Dusk Network
BIT
UC08RX
Unicredit Bank
COIN
UTSETH
UTEMIS
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados